Fusion-negative rhabdomyosarcoma with diffuse bony metastases and remarkable chemosensitivity.

Paige Kube, Katie Parisio, David Spencer Mangum, Jonathan Powell

Open access · greenAbstract readCase Reports

In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 49% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Paige KubeDepartment of Pediatrics, Nemours Children's Hospital Delaware, Wilmington, Delaware, USA.

Katie ParisioDepartment of Hematology/Oncology and Department of Palliative Medicine, Nemours Children's Hospital Delaware, Wilmington, Delaware, USA.

David Spencer MangumDivision of Hematology/Oncology, Department of Pediatrics, University of Utah and Primary Children's Hospital, Salt Lake City, Utah, USA.

Jonathan PowellDepartment of Pediatrics, Nemours Children's Hospital Delaware, Wilmington, Delaware, USA Jonathan.powell@nemours.org.ORCID http://orcid.org/0000-0002-8306-5162

Primary Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this report, we describe the case of an adolescent male with an unusual case of fusion-negative, paratesticular alveolar rhabdomyosarcoma who presented with spontaneous tumour lysis syndrome and diffuse bony metastases throughout the axial and appendicular skeleton with additional significant bone marrow involvement. Both spontaneous tumour lysis syndrome and diffuse bony metastases are extremely unusual for rhabdomyosarcoma. On the backbone of standard vincristine, dactinomycin and cyclophosphamide (VAC) chemotherapy, the only local control was orchiectomy at 15 weeks, with no radiation administered due to the initially diffuse nature of the disease and rapid response to chemotherapy. Following 43 weeks of VAC, a year-long maintenance phase with pazopanib was given which was well tolerated. The patient remains in remission now 4 years after completion of therapy.

Indexed as

Bone Marrow DiseasesBone NeoplasmsGenital Neoplasms, MaleRhabdomyosarcomaRhabdomyosarcoma, EmbryonalTumor Lysis SyndromeAdolescentAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDactinomycinHumansMaleVincristineCyclophosphamideDactinomycinVincristineCancer interventionChemotherapyPaediatric oncology

Identifiers

PMID36038153

DOI10.1136/bcr-2022-250236

PMCPMC9438076

OpenAlexW4293456942

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.